Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 3.18% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 2.42% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 12.25% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -35.06% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 13.47% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 36.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.10 Bn | 214.41 Mn | 40.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.50% |
| Mar 31, 2026 | -119.19% |
| Dec 31, 2025 | 71.49% |
| Sep 30, 2025 | 31.40% |
| Jun 30, 2025 | 27.58% |
| Mar 31, 2025 | 26.00% |
| Dec 31, 2024 | -9.31% |
| Sep 30, 2024 | 40.88% |
| Jun 30, 2024 | 36.74% |
| Mar 31, 2024 | 96.01% |
| Dec 31, 2023 | 7.07% |
| Sep 30, 2023 | 59.10% |
| Jun 30, 2023 | 94.76% |
| Mar 31, 2023 | 54.89% |
| Dec 31, 2022 | 30.51% |
| Sep 30, 2022 | 98.52% |
| Jun 30, 2022 | 97.46% |
| Mar 31, 2022 | 64.85% |
| Dec 31, 2021 | 79.25% |
| Sep 30, 2021 | 70.04% |